Skip to main navigation
Skip to search
Skip to main content
OSU Center for Health Sciences Research Profiles Home
Help & Contact
Home
Profiles
Research units
Projects
Research output
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Lung Cancer: Assessing Core Outcome Sets
Andrew V. Tran
,
Brody Dennis
,
Matthew Rashid
,
Kyle Fitzgerald
,
Kimberly Magana
,
Shaelyn Ward
,
Garrett Jones
,
Jay Modi
,
Trevor Magee
,
Griffin Hughes
,
Alicia Ito Ford
,
Matt Vassar
COM Entering Class of 2022
COM Entering Class of 2021
COM Entering Class of 2020
Research Opportunities
Psychiatry and Behavioral Sciences
Office of Medical Student Research
Research output
:
Contribution to conference
›
Poster
›
peer-review
23
Downloads (Pure)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Lung Cancer: Assessing Core Outcome Sets'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Core Outcome Set
100%
Lung Cancer
100%
Clinical Trials
14%
Cancer Research
14%
Patient Outcomes
14%
Data Reliability
14%
Lung Cancer Clinical Trials
14%
Inclusion Criteria
7%
Randomized Controlled Trial
7%
Trial Adherence
7%
Trial Results
7%
High Mortality
7%
Mortality Burden
7%
Financial Burden
7%
Trial Characteristics
7%
Cancer Clinical Trials
7%
Effectiveness Study
7%
Place of Death
7%
International Consortium for Health Outcomes Measurement (ICHOM)
7%
Cross-section Analysis
7%
Core Outcome Measures
7%
Health Challenges
7%
Health-related Quality of Life Questionnaires
7%
Time Duration
7%
Medicine and Dentistry
Lung Cancer
100%
Clinical Trial
50%
Cancer Research
25%
Prevalence
12%
Randomized Controlled Trial
12%
Outcome Assessment
12%
Quality of Life
12%
Health Outcomes
12%
Nursing and Health Professions
Lung Cancer
100%
Cancer Research
25%
Treatment Outcome
25%
Prevalence
12%
Health Outcomes
12%
Outcome Assessment
12%
Quality of Life
12%
Pharmacology, Toxicology and Pharmaceutical Science
Lung Cancer
100%
Clinical Trial
50%
Prevalence
12%
Randomized Controlled Trial
12%
Biochemistry, Genetics and Molecular Biology
Clinical Trial
100%
Prevalence
25%
Randomized Controlled Trial
25%